TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01369095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Capsule, Oral, 30-60mg/day, once daily, 7 weeks (Phase B), 7weeks (Phase C\&D)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Capsule, Oral, 10-20 mg/day, once daily, 7 weeks (Phase B), 7 weeks (Phase C\&D)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-820836 Placebo
Description: Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B\&C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836 Placebo
Description: Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B\&C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836 Placebo
Description: Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B\&C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836 Placebo
Description: Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B\&C)
Study: NCT04113512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jalaneti
Description: Sterilised and lukewarm isotonic salt water using neti pot was poured into one nostril, so that it leaves through the other. The procedure is then repeated on the other side, and the nose is dried by bending forward and by rapid yoga breathing
Study: NCT00212758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutropin AQ
Description: Nutropin AQ

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutropin AQ
Description: Nutropin AQ
Study: NCT01369095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836 Placebo
Description: Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B\&C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablet, Oral, 0.25mg, once daily, 6 weeks (Phase C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablet, Oral, 0.5 mg, once daily, 6 weeks (Phase C)
Study: NCT00845845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3-acid ethyl esters (Lovaza)
Description: 4 milligrams daily omega-3-acid ethyl esters (Lovaza) with dietary counseling for 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo with dietary counseling for 24 weeks.
Study: NCT01369095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablet, Oral, 1.0 mg, once daily, 6 weeks (Phase C)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-820836
Description: Tablet, Oral, 2.0 mg, once daily, 6 weeks (Phase C)
Study: NCT03201835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PNL-THC:CBD soft gelatin capsule
Description: 3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sativex
Description: spray X 4 actuations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD hard capsule dose 1
Description: 1 hard capsule containing 10 mg CBD
Study: NCT03381625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMX-010
Description: Safety and efficacy of BMX-010 in topical treatment of psoriasis and/or atopic dermatitis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration of placebo in patients with psoriasis and/or atopic dermatitis.
Study: NCT04262791

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist Actigraphy Device
Description: Wrist Actigraphy Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist Actigraphy Device
Description: Wrist Actigraphy Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep Headband
Description: Sleep Headband

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sleep Headband
Description: Sleep Headband
Study: NCT00187850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PP
Description: Partial pulpotomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: DPC
Description: Direct pulp capping
Study: NCT03201835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-PNL-THC:CBD soft gelatin capsule
Description: 2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD hard capsule dose 2
Description: 1 hard capsule containing 100 mg CBD
Study: NCT03728790

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring
Description: Bluetooth-enabled blood pressure cuff to assess whether this technology helps providers collect more data regarding their patients' blood pressures in the postpartum period.
Study: NCT00884871

Intervention type: PROCEDURE
Intervention: LapBand
Description: Prospective observation study of 100 obese women undergoing laparoscopic gastric banding to determine impact of weight loss on pelvic floor disorders
Study: NCT01581645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobilaser
Description: Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
Study: NCT01452828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA single infusion
Description: Single IV infusion, 200 mg daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: Two separate infusions of 200 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR-701 FA
Description: Single IV infusion, 200 mg daily for 7 days
Study: NCT03026400

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transumbilical incision
Description: While both types of incision were considered equal regarding the potential clinical outcome, the investigators considered the transumbilical incision to be the ''intervention'' and the subumbilical incision to be the ''standard care comparator'' since the transumbilical incision take a few more minutes to be completed.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Subumbilical incision
Description: Considered here as the ''control'' intervention.
Study: NCT00689234

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: diaphragm plication 6 months after inclusion
Description: thoracotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: diaphragm plication at time of inclusion
Description: thoracotomy
Study: NCT04770662

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Administered Questionnaires:~* Dutch version of Children's Yale-Brown Obsessive Compulsive Scale (CYBOCS, Goodman W.K. e.a.)~* Dutch version of Eating Disorder Inventory-3 (EDI-3, David M. Garner)~* General Questionnaire: demografic , scholar and social information and child psychiatric history~* Dutch version of the Child Behavior Checklist (CBCL, T.M. Achenbach)~* Anorectic Behavior Observation Scale (ABOS, Vandereycken W., Universitair Centrum Kortenberg, 1992)
Study: NCT03078660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: The smartphone Application generates a shopping list for participants, based on a low caloric diet (energy requirements minus 500 kcals), taking into consideration the Dietary Guidelines for Americans' recommendations and also considering the available budget for each shopping event and the weekly discounts from major supermarkets.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Nutritional Counseling
Description: Participants will have a face-to-face counseling session with a registered dietitian, who will provide recommendations for a low caloric diet (energy requirements minus 500 kcals) using the food group sheets from the Dietary Guidelines for Americans.
Study: NCT02052531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028
Description: Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks
Study: NCT01582958

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT)
Description: Osteopathic Manipulative Treatment (OMT) is the therapeutic application of manually guided forces by an Osteopathic physician to improve physiologic function.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sham omt
Description: Hands are placed on subjects the same as omt arm but no omt is provided.
Study: NCT02052531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028
Description: Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Participants received topical Vehicle twice daily for 4 weeks
Study: NCT03304548

Intervention type: OTHER
Intervention: Telephone concept elicitation interview
Description: All interview questions are designed to be very open-ended in order to ascertain subjects' preferences in an un-biased manner (as possible), with additional probes only being used when necessary to ensure all concepts of interest are covered. Subjects will be asked a series of broad, open-ended questions designed to encourage them to talk openly and as spontaneously as possible about their experience of taking oral treatment(s) for their PAH.
Study: NCT02978430

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computer-assisted GDFT
Description: Patients receive fluid therapy via a computer-assisted goal-directed fluid therapy (GDFT) prototype closed-loop (automated) system guided by a cardiac output monitor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Patients receive fluid management based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output). This control group (started retrospectively before the first included patient of the closed-loop goal directed fluid therapy group) consists of the same population undergoing the same surgery as the closed-loop GDFT group.
Study: NCT05670249

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suboccipital decompressive craniectomy
Description: extensive bilateral suboccipital decompressive craniectomy with duraplasty
Study: NCT04483297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK1320 MS
Description: AK1320 MS + Local Autologous Bone + Posterior Fixation. Ascending Dose.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Local Autologous Bone + Posterior Fixation
Study: NCT03633591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: Multiple doses of tolcapone tablets in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone Modified Release Prototype
Description: A single dose of tolcapone modified release prototype in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone Divided Dose
Description: Tolcapone (suspension) in equal divided doses in the fasted state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone Modified Release Prototype
Description: A single dose of tolcapone modified release prototype (optionally two doses or fed state of prior MR prototype)
Study: NCT00722098

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC Vaccine & Cyclophosphamide
Description: Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: DC Vaccine & Placebo
Description: Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.~Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7.
Study: NCT03267758

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goodbelly first
Description: Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This is followed by 6 weeks of placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo first
Description: Consumption of 1 serving of probiotic placebo daily for 6 weeks. of 1 serving of Goodbelly probiotic daily for 6 weeks.
Study: NCT04240769

Intervention type: DEVICE
Intervention: Total or Partial Knee Arthroplasty
Description: Reconstruction of part or all of the native articulation at the knee joint via implant.
Study: NCT03751111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: Naloxone at an sublingual dose of 40 mg daily for one week will be given to each subject. Subjects will self-administer the drug at supervision in the primary care center.
Study: NCT04644055

Intervention type: DIAGNOSTIC_TEST
Intervention: EUS- share wave of the liver
Description: Evaluation of the right and left hepatic lobe with EUS-guided share wave

Intervention type: DIAGNOSTIC_TEST
Intervention: EUS- share wave of the liver
Description: Evaluation of the right and left hepatic lobe with EUS-guided share wave
Study: NCT01063218

Intervention type: OTHER
Group type: OTHER
Intervention: Emollient - Cetaphil Advanced
Description: Emollient - Cetaphil Advanced - to be applied twice a day for 20 weeks.
Study: NCT00905268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idebenone
Description: 12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idebenone
Description: 12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idebenone
Description: 12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
Study: NCT03751111

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given to each subject for one week. Subjects will self-administer the drug at supervision in the primary care center.
Study: NCT03323710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol will be administered orally at a starting dose of 40 mg (one tablet) two times a day (total daily dose of 80 mg). In case of acceptable safety profile, the dose may be increased to 80 mg (two tablets) two times a day (total daily dose of 160 mg) or farther to 80 mg (two tablets) three times a day (total daily dose of 240 mg).
Study: NCT00905268

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
Study: NCT03550365

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye bran bread intervention
Description: 4 week dietary intervention rich in rye bran bread

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rye bread intervention
Description: 4 week dietary intervention rich in rye bread

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wheat bread diet
Description: 4 week dietary intervention rich in wheat bread as an active comparator for previous two interventions
Study: NCT01107288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music-based multitask exercises program
Description: Subjects are entered into a 6-month Jaques-Dalcroze eurhythmics program and are followed for an additional 6 months after the intervention period. They complete assessments at baseline, 6 and 12 months. The program consists of structured 1-hour group exercises classes, conducted weekly by an experimented instructor, that include varied multitask exercises performed to the rhythm of improvised piano music, sometimes with the manipulation of objects (e.g., instruments of percussion, balls), with gradually increasing difficulty over time. Basic exercises consist of walking following the music, responding directly to changes in music's rhythmic patterns.

Intervention type: OTHER
Group type: OTHER
Intervention: Music-based multitask exercises program
Description: Subjects are wait-listed to receive, 6 months after randomization, the same 6-month Jaques-Dalcroze eurhythmics program as the Intervention group. They complete assessments at baseline, 6 and 12 months.
Study: NCT03323710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib will be administered orally at a starting dose of 50 mg once daily, for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks.The schedule may be changed to 2 weeks on / 1 week off (schedule 2/1) and a daily dose may be reduced to 37.5 mg or 25 mg to decrease the level of toxic side effects.
Study: NCT01578187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hair2Go
Description: Treatment with the device once under observation
Study: NCT00798980

Intervention type: DRUG
Intervention: Mirena (BAY86-5028)
Description: Nulliparous Women
Study: NCT03689348

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Avena sativa
Description: A supplement derived from wild green oat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Avena sativa
Description: A supplement derived from wild green oat

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Avena sativa
Description: A supplement derived from wild green oat

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin
Study: NCT00496470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort (budesonide/formoterol turbuhaler 320/9ug)
Description: Symbicort (budesonide/formoterol turbuhaler 320/9ug)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva (tiotropium bromide 18ug)
Description: Spiriva (tiotropium bromide 18ug)
Study: NCT03990454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SLC-391
Description: SLC-391 is an AXL inhibitor
Study: NCT00005639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: subcutaneous injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: subcutaneous injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: subcutaneous injection (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylbutyrate
Description: continuous intravenous (CIV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylbutyrate
Description: continuous intravenous (CIV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylbutyrate
Description: continuous intravenous (CIV)
Study: NCT03118648

Intervention type: DIAGNOSTIC_TEST
Intervention: Scale Action Research Arm Test (ARAT)
Description: Measuring the functional recovery of the paretic upper limb rehabilitation outing with the scale ARAT
Study: NCT04068870

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contraceptive management program
Description: The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) incentivized visits.
Study: NCT02591290

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular (2 doses with 8-week interval)
Study: NCT02688478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phthalate
Description: Delivered by inhalation on day 1 of the triad

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Filtered Air
Description: Delivered by inhalation on day 1 of the triad

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allergen
Description: Subject specific allergen is delivered by inhalation on day 1 of the triad

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergen
Description: Subject specific allergen is delivered by inhalation on day 1 of the triad
Study: NCT03643016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical strategy based on a software
Description: Surgical strategy décision based on a software
Study: NCT01433692

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief Intervention
Description: CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).
Study: NCT01832974

Intervention type: DRUG
Group type: OTHER
Intervention: IL-13-PE
Description: IL-13-PE intravenous infusion

Intervention type: DRUG
Group type: OTHER
Intervention: IL-13-PE
Description: IL-13-PE intravenous infusion
Study: NCT01433692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Intervention
Description: CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).
Study: NCT00541736

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerine
Description: Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerine
Description: Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min
Study: NCT04248686

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CoED Online Intervention
Description: Online, guided self-help ED intervention that offers cognitive behavioral therapy (CBT) based tools to improve ED symptoms, while also teaching the healthy methods of behavioral WL, for individuals with clinical/sub-clinical binge-type EDs with comorbid overweight/obesity